An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.

ABSTRACT:

Introduction

Japanese encephalitis (JE) virus is the most common cause of vaccine-preventable encephalitis in Asia. The SA14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products has been shown to be safe and effective in clinical trials and childhood routine immunization programs. However, there are few published reports describing results of surveillance for adverse events following immunization (AEFI) when the vaccine is used in mass campaigns. We describe the results of AEFI surveillance following a 2013 vaccination campaign among almost 310,000 children aged 9 months-12 years in Battambang Province, Cambodia.

Methods

Routine AEFI surveillance was strengthened by staff training and supplemented by active hospital surveillance. An AEFI was defined as an

SUBMITTER: Hills SL 

PROVIDER: S-EPMC9182652 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature